Ball succeeds Maderis as CEO of Antiva
Plus: Valente joins Xencor and updates from Sutro, Gameto and more
Antiva Biosciences Inc. announced the transition of President and CEO Gail Maderis to the role of chairman, along with the closing of a $53 million series E round. Maderis is succeeded as CEO by Kristine Ball, who will join the company’s board along with Florencia Segal and Brian Goodman from series E leader MPM-BioImpact Capital. Ball was CEO of Soteria Biotherapeutics Inc. and held leadership positions at Menlo Therapeutics Inc., Relypsa Inc. and KAI Pharmaceuticals Inc. Antiva is developing topical treatments for pre-cancerous lesions caused by HPV.
Xencor Inc. (NASDAQ:XNCR) hired Nancy Valente as EVP, chief development officer, effective May 1. Valente concluded an 18-year career at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY)
in 2021 and is a director at Myovant Sciences GmbH and Immatics N.V. (NASDAQ:IMTX). She joined Xencor’s board in September 2022, a role from which she has resigned. Xencor is developing engineered antibodies and cytokines to treat cancer and autoimmune diseases...